BLUECHEW blog

You’ve most likely heard of the sexual performance enhancers Viagra (Sildenafil), Levitra (Vardenafil), and Cialis (Tadalafil) and their impressive ability to boost your erections and performance in the bedroom.

But did you know that these medications may have other potential health benefits?

Notably, recent research has found these medications may play a role in preventing and treating colon cancer, currently the leading cause of cancer death in men under 50.

Although not currently FDA-approved for this use, we’ll dive into the research behind why these medications may reduce your risk while also giving you a confidence boost between the sheets. Plus, we’ll give you the scoop on how to access these medications for sexual enhancement and have them delivered right to your door with BlueChew.com.

What Are Sexual Performance Enhancers?

Sexual performance enhancers like Sildenafil, Tadalafil, and Vardenafil belong to a class of medications known as phosphodiesterase type 5 (PDE5) inhibitors. These medications prevent a vital enzyme in the body known as phosphodiesterase 5 (PDE5) from doing its job.

The primary role of PDE5 is to break down a chemical messenger known as cyclic guanosine monophosphate (cGMP). This causes relaxation of the vascular smooth muscle cells, resulting in dilation (widening) of the blood vessels. When our vessels widen, we experience an increase in blood flow to that area.

In terms of enhancing erections, there is a large quantity of PDE5 in the smooth muscle cells that line the blood vessels of the penis. As the vessels dilate, more blood can flow into the penis resulting in harder, longer-lasting erections. 

The Connection Between PDE5 Inhibitors and Colorectal Cancer Prevention

Can a medication that helps you get harder erections actually prevent you from developing colorectal cancer?

According to some substantial research, it is possible that it can.

A groundbreaking 2019 study revealed that patients taking PDE5 inhibitors—medications like Sildenafil and Tadalafil—had a significantly lower risk of developing colorectal cancer. The numbers are hard to ignore: only 2.64 per 1,000 men per year who used these medications developed colorectal cancer, compared to 4.46 per 1,000 men per year who didn’t. That’s nearly double the risk for patients who skipped out on these medications.

But here’s where it gets even more interesting: the protection appears to be dose-dependent. Researchers found the higher the cumulative dose of PDE5 inhibitors (AKA the total amount taken over time), the lower the risk of developing colorectal cancer. In simple terms, more consistent use meant greater protection.

This wasn’t just a one-off finding. A comprehensive 2023 review analyzing the results of six studies found that patients who had ever used PDE5 inhibitors had a statistically significant lower incidence of colorectal cancer and were less likely to develop precancerous polyps, the precursors to the disease.

The takeaway? Although not currently FDA-approved for this use, PDE5 inhibitors might also play a life-saving role in reducing colorectal cancer risk.

How PDE5 Inhibitors May Reduce Cancer Risk

This is all great news for the prevention and potential treatment of colorectal cancer, but how do these medications work? Here is what researchers know so far. 

Inhibiting Phosphodiesterases

There is a growing body of evidence supporting the notion that special enzymes known as phosphodiesterases (PDEs) are involved in the progression of colorectal cancer. 

Erection-enhancing medications work by inhibiting the action of a specific type of phosphodiesterase inhibitor, PDE5. Because these medications prevent the action of an enzyme that causes colorectal cancer to progress, they may reduce the risk of developing the disease. 

Stop Tumor Growth

Research has shown that erection-enhancing medications may possess impressive anti-tumor properties, meaning they can actively stop or even prevent the growth of cancerous tumors.

How? It all comes down to energy. 

Cancer cells are energy hogs, relying on their metabolism to fuel rapid growth. PDE5 inhibitors disrupt this process, effectively cutting off the energy supply cancer cells need to thrive.

By interfering with the metabolism of cancerous cells, these medications may put the brakes on the growth of tumor cells in the colon. It’s like flipping a switch—without energy, tumor growth grinds to a halt.

Promotes Cancer Cell Death

PDE5 inhibitors have shown promise in fighting colorectal cancer by causing cell cycle arrest (stopping cancer cell growth) and triggering death. 

The secret lies in their effect on reactive oxygen species (ROS), unstable molecules that can wreak havoc on a cell’s critical components. By increasing ROS levels, PDE5 inhibitors damage cancer cells, rendering them unable to function and ultimately leading to their death.

Sildenafil, in particular, has shown remarkable results. Studies found that it effectively halted the growth of human colorectal cancer cells, both in lab dishes and live mice. 

This groundbreaking research highlights Sildenafil’s potential as an effective treatment option for colorectal cancer, offering hope for future advancements in cancer care.

Reduces Inflammation 

Did you know PDE5 inhibitors like Sildenafil have been shown to reduce inflammation in conditions such as benign prostatic hyperplasia (BPH) and nervous system disorders? 

Interestingly, colorectal cancer is also fueled by inflammation. Chronic conditions like ulcerative colitis, an inflammatory bowel disease, can skyrocket your risk of developing colon cancer.

A 2017 study revealed Sildenafil’s power in potentially preventing colorectal cancer, particularly in individuals with inflammatory bowel diseases, due to its ability to halt inflammation. Researchers found that Sildenafil reduced colon polyp formation by 50%, making existing polyps less aggressive and inflamed. 

These findings suggest that PDE5 inhibitors may be able to prevent inflammation-driven colorectal cancer right at the source.

Targets cGMP

Cyclic guanosine monophosphate (cGMP) is a vital chemical mediator that is impacted by PDE5 inhibitors. It’s crucial for causing relaxation of blood vessels to help patients achieve harder, longer-lasting erections, and it also plays a role in promoting the health of the lining of the gastrointestinal tract. 

Cancer researchers have discovered that when cGMP levels are raised (which happens when you take a PDE5 inhibitor), it may improve the health of the lining of the gastrointestinal tract, making it less likely for tumor cells to grow. 

Research has also demonstrated that elevated levels of cGMP contribute to stopping the cell cycle (or the production of more cells) which prevents cancer cells from rapidly dividing.

These findings show PDE5 inhibitors may be a great way to prevent colon cancer, especially in individuals at increased risk like those with a family history of colon cancer, inflammatory bowel disease, or chronic inflammation.

Why Should We Care About Colorectal Cancer?

Here’s a not-so-fun fact: colorectal cancer is a major cause of death, especially for men under 50. According to the American Cancer Society, it’s the leading cause of cancer death in this age group. 

If that doesn’t make you want to pay attention, according to the National Cancer Institute, colon cancer is the third most common cancer worldwide and one of the deadliest, with a five-year survival rate hovering around only 60%. That means nearly half of those who receive this cancer diagnosis won’t live beyond five years.

Another alarming reason why finding new and effective prevention and treatment methods is crucial is that it isn’t just a problem for older people anymore. Scientific data shows in recent years there has been a surge in colorectal cancer cases among people under 50. 

The numbers don’t lie – colorectal cancer is a growing threat, especially for younger men, and it’s time to start paying attention. 

Whether it’s through lifestyle changes, early screenings, or exploring the potential of PDE5 inhibitors to lower your risk, taking action now could literally save your life.

What Does This Mean For Colorectal Cancer Prevention and Treatment?

While PDE5 inhibitors like Sildenafil, Tadalafil, and Vardenafil aren’t yet FDA-approved for preventing or treating colorectal cancer, the research so far is incredibly promising. These drugs, already widely known for their safety and effectiveness in enhancing erections, might just pull double duty by reducing your risk of colorectal cancer too.

Here’s the good news: even if you’re taking these medications solely for performance in the bedroom, you could still be reaping some serious health benefits. Studies suggest that taking PDE5 inhibitors consistently over time can significantly lower your chances of developing colorectal cancer. And the longer you take them, the less likely you are to develop it. 

It doesn’t matter which PDE5 inhibitor you take—Sildenafil, Tadalafil, or Vardenafil—all have been shown to be equally effective in reducing colorectal cancer risk. 

BlueChew’s DailyTAD stands out as a perfect option for patients aiming to lower their risk, thanks to its unique daily-use formulation packed with 9 mg of Tadalafil and seven immune-boosting vitamins—all in one convenient chewable tablet.

Interested in learning more about DailyTAD? Click here.

For patients already facing a colorectal cancer diagnosis, PDE5 inhibitors might offer additional hope. Research has demonstrated that when combined with other cancer treatments, Sildenafil may improve treatment outcomes (as in help existing cancer treatments work better). While Tadalafil has been shown to prevent metastasis (or the spread of colon cancer) to other parts of the body.

The bottom line: PDE5 inhibitors are an exciting, emerging option in the fight against colorectal cancer, and offer a potential win-win for prevention, treatment, and improvement of sexual health.

Final Thoughts

Who knew the well-known little blue pill could do so much for our colon health? 

PDE5 inhibitors like Sildenafil, Tadalafil, and Vardenafil have been changing lives in the bedroom for decades, and now they might be changing the way we approach colorectal cancer prevention and treatment.

From reducing inflammation to stopping cancer cell growth, these medications offer more than just a confidence boost in the bedroom—they could save lives. Whether you’re taking them for enhanced erections or as part of a potential preventive health plan, the science shows that PDE5 inhibitors, like DailyTAD,  may pack a powerful punch in the fight against colorectal cancer.

While more randomized controlled trials are needed before they become a standard cancer-prevention tool, it’s clear that PDE5 inhibitors have a bright future beyond the bedroom. 

Before starting any medications for the treatment or prevention of colorectal cancer, it is essential to speak with your healthcare provider to ensure these medications are safe for you. PDE5 inhibitors are not currently FDA-approved for this use, so it’s crucial to seek medical advice regarding your colon health.

The good news is so far the science shows PDE5 inhibitors may lead to better erections, better health, and one more reason to feel good about your performance-enhancing pills.

How To Get PDE5 Inhibitors From BlueChew

Want to potentially slash your colorectal cancer risk and ramp up your bedroom game? BlueChew has your back.

With options like DailyTAD—designed for daily dosing—BlueChew makes it easy to reap potential health benefits while also boosting your performance between the sheets.

Getting started is simple: visit our website, select a plan, and complete an online intake. A medical provider will review your information and, if appropriate, prescribe your plan, which will be shipped directly to your door.

No doctor appointments or patient support charges make it a stress-free experience.

With plans starting as low as $25 per month, BlueChew can fit into anyone’s budget. Plus, there’s no commitment—you can easily cancel or switch plans anytime.
Click here to explore all plan options for treatments at BlueChew.

FAQ

Do PDE5 inhibitors lower the risk of colorectal cancer?

Although not FDA-approved for this use, research suggests they may reduce this risk. Research indicates that patients taking PDE5 inhibitors may experience a lower risk of developing colorectal cancer. These medications have been shown to influence tumor formation and help maintain healthy colon tissue, possibly contributing to a reduced risk of colorectal cancer.

Can PDE5 inhibitors affect cancer incidence?

PDE5 inhibitors may decrease cancer incidence (the number of new cancer cases in a specific time frame) by targeting specific mechanisms like cell proliferation and inflammation, which are crucial in the development of tumor cells. This makes them a potential tool for cancer prevention.

What risk factors for colorectal cancer do PDE5 inhibitors address?

These medications may be particularly effective for individuals with chronic diseases like inflammatory bowel disease, which significantly increases colon cancer risk. Colitis associated cancer is all about inflammation so by reducing inflammation, PDE5 inhibitors can address these critical risk factors. Always consult with a healthcare provider before starting any new medications.

Can PDE5 inhibitors prevent tumors in the colon?

According to research, PDE5 inhibitors have been shown to promote the health of the colon tissue and reduce inflammation, which may lower the likelihood of tumor growth. 

Are PDE5 inhibitors recommended for cancer prevention?

While the scientific community is excited about the potential of these drugs, more cancer research is needed before they become a standard recommendation for cancer prevention. They are currently not FDA-approved for this use. 

How much of a decreased risk of colon cancer can someone expect with PDE5 inhibitors?

Because they are not currently FDA-approved for this use, research is still limited. So far, studies have shown a statistically significant decreased risk of colorectal cancer in patients taking these medications, especially with consistent use over time. Some scientific data has demonstrated up to a 36% reduced risk of colorectal cancer. This risk reduction appears to be dose-dependent, meaning higher cumulative doses (over a lifetime) provide greater protection. Always consult a healthcare provider before starting any new medications for treatment or prevention of any medical condition.

This article is for informational purposes only and does not constitute medical advice. The content provided here is not a substitute for, and should never be relied upon as, professional medical advice. Always consult your doctor to discuss the risks, benefits, and appropriateness of any treatment. BlueChew offers compounded medications prescribed solely for the treatment of erectile dysfunction and sexual performance enhancement. Compounded medications are not FDA-approved.

References

1. American Cancer Society. Colorectal Cancer Screening* (%), Adults 45 Years and Older by State, 2020 Screening Prevalence.; 2023. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2023.pdf
2. Dhaliwal A, Gupta M. PDE5 Inhibitor. PubMed. Published 2020. https://www.ncbi.nlm.nih.gov/books/NBK549843/
3. Huang W, Sundquist J, Sundquist K, Ji J. Use of Phosphodiesterase 5 Inhibitors Is Associated with Lower Risk of Colorectal Cancer in Men with Benign Colorectal Neoplasms. Gastroenterology. 2019;157(3):672-681.e4. doi:https://doi.org/10.1053/j.gastro.2019.05.012
4. Cullinane C, Brett A, Devane L, McCullough PW, Cooke F, Neary P. The Protective Role of Phosphodiesterase Inhibitors in Preventing Colorectal Cancer and Advanced Colorectal polyps: a Systematic Review and Meta‐analysis. Colorectal Disease. 2023;25(10):1949-1959. doi:https://doi.org/10.1111/codi.16724
5. Sutton SS, Magagnoli J, Cummings TH, Hardin JW. The Association Between Phosphodiesterase-5 Inhibitors and Colorectal Cancer in a National Cohort of Patients. Clinical and Translational Gastroenterology. 2020;11(6):e00173. doi:https://doi.org/10.14309/ctg.0000000000000173
6. Huang W, Sundquist J, Sundquist K, Ji J. Phosphodiesterase-5 Inhibitors Use and Risk for Mortality and Metastases among Male Patients with Colorectal Cancer. Nature Communications. 2020;11(1). doi:https://doi.org/10.1038/s41467-020-17028-4
7. Zhao P, Shen Y, Li M, Dan H, Zhao Z, Zhang J. Integration of Transcriptomics and Metabolomics Reveals the Antitumor Mechanism Underlying Tadalafil in Colorectal Cancer. Frontiers in Pharmacology. 2022;13. doi:https://doi.org/10.3389/fphar.2022.793499
8. Zhu B, Vemavarapu L, Thompson WJ, Strada SJ. Suppression of Cyclic GMP-specific Phosphodiesterase 5 Promotes Apoptosis and Inhibits Growth in HT29 Cells. Journal of Cellular Biochemistry. 2005;94(2):336-350. doi:https://doi.org/10.1002/jcb.20286
9. Mei XL, Yang Y, Zhang YJ, et al. Sildenafil Inhibits the Growth of Human Colorectal Cancer in Vitro and in Vivo. American Journal of Cancer Research. 2015;5(11):3311. Accessed November 20, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC4697679/
10. Vignozzi L, Gacci M, Cellai I, et al. PDE5 Inhibitors Blunt Inflammation in Human BPH: A Potential Mechanism of Action for PDE5 Inhibitors in LUTS. The Prostate. 2013;73(13):1391-1402. doi:https://doi.org/10.1002/pros.22686
11. Peixoto CA, Nunes AKS, Garcia-Osta A. Phosphodiesterase-5 Inhibitors: Action on the Signaling Pathways of Neuroinflammation, Neurodegeneration, and Cognition. Mediators of Inflammation. 2015;2015:1-17. doi:https://doi.org/10.1155/2015/940207
12. Islam BN, Sharman SK, Hou Y, et al. Sildenafil Suppresses Inflammation-Driven Colorectal Cancer in Mice. Cancer Prevention Research. 2017;10(7):377-388. doi:https://doi.org/10.1158/1940-6207.capr-17-0015
13. Browning DD. The Enduring Promise of Phosphodiesterase 5 Inhibitors for Colon Cancer Prevention. Translational Gastroenterology and Hepatology. 2019;4:83-83. doi:https://doi.org/10.21037/tgh.2019.12.10
14. Peak TC, Richman A, Gur S, Yafi FA, Hellstrom WJG. The Role of PDE5 Inhibitors and the NO/cGMP Pathway in Cancer. Sexual Medicine Reviews. 2016;4(1):74-84. doi:https://doi.org/10.1016/j.sxmr.2015.10.004
15. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: A Cancer Journal for Clinicians. 2018;68(1):7-30. doi:https://doi.org/10.3322/caac.21442
16. Weinberg A. IC107: Cancer Facts: Fatigue and Cancer. DigitalCommons@TMC. Published 2024. Accessed November 20, 2024. https://digitalcommons.library.tmc.edu/info_promo/8/
17. Cruz-Burgos M, Losada-Garcia A, Cruz-Hernández CD, et al. New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil. Frontiers in Oncology. 2021;11. doi:https://doi.org/10.3389/fonc.2021.627229
18. Rashid A. The Efficacy and Safety of PDE5 Inhibitors. Clinical Cornerstone. 2005;7(1):47-56. doi:https://doi.org/10.1016/s1098-3597(05)80048-1
19. Bhagavathula AS, Tesfaye W, Vidyasagar K. Phosphodiesterase Type 5 Inhibitors Use and Risk of Colorectal cancer: a Systematic Review and meta-analysis. International Journal of Colorectal Disease. 2021;36(12):2577-2584. doi:https://doi.org/10.1007/s00384-021-04022-5
20. Tavallai M, Hamed HA, Roberts JC, et al. Nexavar/Stivarga and Viagra Interact to Kill Tumor Cells. Journal of Cellular Physiology. 2015;230(9):2281-2298. doi:https://doi.org/10.1002/jcp.24961
21. Paronetto MP, Crescioli C. Rethinking of Phosphodiesterase 5 Inhibition: The Old, the New and the Perspective in Human Health. Frontiers in Endocrinology. 2024;15. doi:https://doi.org/10.3389/fendo.2024.1461642